Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

S Zeuzem; IM Jacobson; T Baykal; RT Marinho; F Poordad; M Bourlier̀e; MS Sulkowski; H Wedemeyer; E Tam; P Desmond; DM Jensen; AM Di Bisceglie; P Varunok; T Hassanein; J Xiong; T Pilot-Matias; B DaSilva-Tillmann; L Larsen; T Podsadecki; B Bernstein

Journal article

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

S Zeuzem, IM Jacobson, T Baykal, RT Marinho, F Poordad, M Bourlier̀e, MS Sulkowski, H Wedemeyer, E Tam, P Desmond, DM Jensen, AM Di Bisceglie, P Varunok, T Hassanein, J Xiong, T Pilot-Matias, B DaSilva-Tillmann, L Larsen, T Podsadecki, B Bernstein

New England Journal of Medicine | Published : 2014

DOI: 10.1056/NEJMoa1401561

Abstract

BACKGROUND: In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267), dasabuvir (also known as ABT-333), and ribavirin for the retreatment of HCV in patients who were previously treated with peginterferon-ribavirin. METHODS: We enrolled patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon-ribavirin and had a relapse, a partial response, or a null response. Patients were randomly assigned in a 3:1 ratio to receive coformulated ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombita..

View full abstract